Zelda Therapeutics Ltd

Receive alerts
Market Cap:
$53.01 m
52 weeks high
52 weeks low

Filter by article type

Viewing results 1-25 of 111


Zelda Therapeutics achieves patient milestone in autism treatment cannabis study

Parents of more than 100 kids aged about 10 are reporting how the treatments affect the children’s behaviour....

on 08/21/2019

Zelda Therapeutics teams up with medicinal cannabis clinic network

The agreement supports Zelda’s path to rapid commercialisation through the development of clinically validated cannabis medicines....

on 07/18/2019

Zelda Therapeutics responds to ASX query on price and volume increases

The Australian bio-pharmaceutical company is developing proprietary cannabinoid formulations to treat a variety of medical conditions....

on 07/11/2019

Zelda Therapeutics to begin opioid reduction trial with approval granted

The phase I trial will begin immediately with preliminary results expected later this quarter and full results in quarter four of 2019. ...

on 07/01/2019

Zelda Therapeutics gains new strategic investor in Merchant Funds Management

The company’s medicinal cannabis products are aimed at treating pain, anxiety, sleep apnea and cancer. ...

on 06/10/2019

Zelda Therapeutics on rapid path to medicinal cannabis commercialisation

The company has a focus on clinical validation and is well placed to service a rapidly growing market....

on 05/16/2019

Proactive CEO Sessions next week feature growing bio-pharma and exploration companies

The Sydney CEO Session is on Monday, May 13, and the Melbourne session is Tuesday, May 14....

on 05/09/2019

Zelda Therapeutics to use Federal Government R&D tax rebate of $769,000 to drive clinical trials

The Australian-based bio-pharmaceutical company has also formed a strategic relationship with European medicinal cannabis group HAPA Medical BV to access HAPA’s EU-GMP grade manufacturing capabilities. ...

on 05/08/2019

Xanadu Mines in prime position with Mongolian copper project iced with gold

Copper market fundamentals add to the potential economic viability of the Kharmagtai project....

on 05/05/2019

Xanadu Mines chairman shows faith in copper-gold strategy with on-market transaction

Darryl Clark has this week purchased 100,000 shares and now holds more than 2.021 million....

on 05/02/2019

Invitrocue to discuss its unique Onco-PDO cancer test at Proactive CEO Sessions

The company’s Onco-PDO cancer screening service supports personalised clinical decisions for patients....

on 05/02/2019

Zelda Therapeutics to outline cannabinoid-based strategy at Proactive CEO Sessions

The company was recently awarded a patent for a novel prognostic biomarker for breast cancer....

on 05/02/2019

Oventus Medical will update on new products and increasing revenue at Proactive CEO Sessions

The company’s O2 Vent Optima device was launched in both Australia and Canada during the March quarter....

on 05/02/2019

Proactive CEO Sessions next month feature bio-pharma and exploration companies

The Sydney CEO Session is on Monday, May 13, and the Melbourne session is Tuesday, May 14....

on 04/24/2019

Zelda Therapeutics in deal with Ilera to access US market

Ilera is a vertically integrated medicinal cannabis company with operations based in Pennsylvania and Louisiana....

on 03/11/2019

Zelda Therapeutics secures patent to detect breast cancer

Building an intellectual property portfolio is part of Zelda's vertically integrated strategy....

on 03/05/2019

Zelda Therapeutics leveraged to study results that progress cannabis-based cancer therapies

The study identifies a novel role for the CB2 cannabinoid receptor in HER2+ breast cancer, putting the company at the forefront of efforts to develop new cannabis treatments. ...

on 02/27/2019

Zelda Therapeutics reflects on busy December half

The company’s cash at bank was $4.41 million at the end of the 2018 calendar year....

on 02/24/2019

Zelda Therapeutics links up with International Cannabis and Cannabinoids Institute

The ICCI provides access to a global network of specialist services. ...

on 02/11/2019

Zelda Therapeutics on track to report on multiple clinical trials

Zelda has released its December quarterly report confirming multiple trials are on track....

on 01/30/2019

Zelda Therapeutics investing in medicinal cannabis oral spray

A deal has been done with SUDA, a global leader in oro-mucosal drug delivery....

on 12/05/2018

Zelda Therapeutics partners with St Vincent’s Hospital for opioid reduction study

The clinical trial partnership will examine the potential to use cannabinoid-based medications....

on 11/25/2018

Zelda Therapeutics founders commit to not selling their shares

The company is focused on developing a range of cannabinoid-based medical treatments. ...

on 11/06/2018